Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial - Concepedia

Concepedia

Publication | Closed Access

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial

307

Citations

30

References

2001

Year

Jacek Jassem, Tadeusz Pieńkowski, A Płużańska, S. Jelić, Vera Gorbunova, Zrinka Mršić-Krmpotić, J. Bērziņš, Tomas Nagykalnai, Nelly Wigler, J. Renard,

Journal of Clinical Oncology

Abstract

AT conferred a significant advantage in response rate, time to progression, and overall survival compared with FAC. Treatment was well-tolerated with no unexpected toxicities.

References

	Year	Citations

Page 1